Soy isoflavone intake inhibits bone resorption and stimulates bone formation in menopausal women: meta-analysis of randomized controlled trials.
Eur J Clin Nutr
; 62(2): 155-61, 2008 Feb.
Article
em En
| MEDLINE
| ID: mdl-17392695
ABSTRACT
OBJECTIVE:
To clarify the effects of isoflavone intake on bone resorption and bone formation.METHODS:
We identified randomized controlled trials related to urinary deoxypyridinoline (Dpyr, a bone resorption marker) and serum bone-specific alkaline phosphatase (BAP, a bone formation marker) listed on MEDLINE (January 1966-April 2006), the Cochrane Controlled Trials Register, EMBASE (1985-January 2006), Science Citation Index and PUBMED (updated till April 2006).RESULTS:
Nine studies with a total of 432 subjects were selected for meta-analysis. The urinary Dpyr concentration in subjects who consumed isoflavones decreased significantly by -2.08 nmol/mmol (95% confidence interval (CI) -3.82 to -0.34 nmol/mmol) in comparison with that in subjects who did not consume isoflavones. Isoflavone intake vs placebo intake significantly increased serum BAP by 1.48 microg/l (95% CI 0.22-2.75 mug/l). Decreases in the urinary Dpyr concentration with isoflavone intake of <90 mg/day and with treatment lasting less than 12 weeks were -2.34 nmol/mmol (95% CI -4.46 to -0.22 nmol/mmol) and -2.03 nmol/mmol (95% CI -3.20 to -0.85 nmol/mmol), respectively.CONCLUSIONS:
Isoflavone intervention significantly inhibits bone resorption and stimulates bone formation. These favorable effects occur even if <90 mg/day of isoflavones are consumed or the intervention lasts less than 12 weeks.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Osteogênese
/
Reabsorção Óssea
/
Menopausa
/
Aminoácidos
/
Isoflavonas
Tipo de estudo:
Clinical_trials
/
Systematic_reviews
Limite:
Female
/
Humans
/
Middle aged
Idioma:
En
Revista:
Eur J Clin Nutr
Ano de publicação:
2008
Tipo de documento:
Article